ceralasertib

News

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

News

UK start-up Potential Sciences emerged from stealth today with a sizeable seed funding round and an ambition to transform drug discovery with AI.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.